Group items tagged

Aspirin therapy is associated with a reduced risk of hepatitis B virus-related hepatocellular carcinoma (HCC), according to a study scheduled for presentation at The Liver Meeting, held by the American Association for the Study of Liver Diseases from Oct. 20 to 24 in Washington, D.C. Teng-Yu Lee, M.D., Ph.D., from Taichung Veterans General Hospital in Taiwan, and colleagues used data from Taiwan's National Health Insurance Research Database from 1998 to 2012. Patients with non-hepatitis B infections were excluded, as were those with HCC before the follow-up index dates. A total of 1,553 patients who continuously received daily aspirin ≥90 days were randomly matched (1-to-4 ratio) with 6,212 patients who never received anti-platelet therapy based on baseline characteristics, the index date, and nucelos(t)ide analogue (NA) use during follow-up. The researchers found that the cumulative incidence of HCC in the treated group was significantly lower than that in the untreated group in five years (2.86 percent versus 5.59 percent). Aspirin therapy was independently associated with a reduced HCC risk (hazard ratio [HR], 0.63) in a multivariable regression analysis. An increased HCC risk was independently associated with older age (HR, 1.03 per year), male gender (HR, 2.65), cirrhosis (HR, 1.89), and diabetes mellitus (HR, 1.51). NA (HR, 0.57) and statin (HR, 0.57) use were associated with a decreased HCC risk.

American Psychiatric Association (APA) 171th Annual Meeting is organized by American Psychiatric Association (APA) and would be held during May 5 - 9, 2018 at New York, United States of America.

23rd European Hematology Association (EHA) Congress is organized by European Hematology Association (EHA) and would be held during Jun 14 - 17, 2018 at Stockholm International Fairs, Stockholm, Sweden.

For young patients with type 1 diabetes, insulin pump therapy is associated with lower risks of severe hypoglycemia and diabetic ketoacidosis and better glycemic control than insulin injection therapy, according to a study published online Oct. 10 in the Journal of the American Medical Association. Beate Karges, M.D., from RWTH Aachen University in Germany, and colleagues conducted a population-based cohort study in 446 diabetes centers. They identified patients with type 1 diabetes who were younger than 20 years and had diabetes duration of more than one year. The researchers found that 14,119 patients used pump therapy and 16,460 used insulin injections. A total of 9,814 patients using pump therapy were matched with 9,814 using injection therapy. Compared with injection therapy, pump therapy was correlated with lower rates of severe hypoglycemia (9.55 versus 13.97 per 100 patient-years) and diabetic ketoacidosis (3.64 versus 4.26 per 100 patient-years). Lower levels of glycated hemoglobin were seen with pump versus injection therapy (8.04 versus 8.22 percent). Compared with injection therapy, pump therapy was associated with lower total daily insulin doses (0.84 versus 0.98 U/kg). No significant difference in body mass index was seen between the treatment regimens

Too many carbs, not fats, may be the culprit in raising risk of premature death, according to a study published online Aug. 29 in the The Lancet to coincide with the European Society of Cardiology Congress 2017, held from Aug. 26 to 30 in Barcelona, Spain. Mahshid Dehghan, Ph.D., an investigator with the Population Health Research Institute at McMaster University in Hamilton, Canada, and colleagues tracked the diet and health of 135,335 people, aged 35 to 70, from 18 countries around the world, to gain a global perspective on the health effects of diet. Participants provided detailed information on their social and economic status, lifestyle, medical history, and current health. They also completed a questionnaire on their regular diet, which researchers used to calculate their average daily calories from fats, carbohydrates, and proteins. The research team then tracked the participants' health for about seven years on average, with follow-up visits at least every three years. The investigators found that high-carbohydrate diets are common, with more than half of the people deriving 70 percent of their daily calories from carbs. People with a high fat intake -- about 35 percent of their daily diet -- had a 23 percent lower risk of early death and 18 percent lower risk of stroke compared to people who ate less fat. The researchers also noted that a very low intake of saturated fats (below 3 percent of daily diet) was associated with a higher risk of death in the study, compared to diets containing up to 13 percent daily. At the same time, high-carb diets -- containing an average 77 percent carbohydrates -- were associated with a 28 percent increased risk of death versus low-carb diets. "The study showed that contrary to popular belief, increased consumption of dietary fats is associated with a lower risk of death," Dehghan told HealthDay. "We found no evidence that below 10 percent of energy by saturated fat is beneficial, and going below 7 percent may even be har

It was not a big problem in order to improve and support my health during the winter. Due to the problems with health, I am trying to maintain my condition.

Unfortunately, there are diseases that are relevant at any time of the year and can affect people with any immunity and at any age. For example https://easystd.com/gonorrhea Of course a lot depends on us in this case, but I agree that to suffer from something like this is extremely unpleasant and treatment may also cost a lot of money.

For patients undergoing right heart catheterization (RHC), borderline pulmonary hypertension (PH) is associated with increased risk of mortality, according to a study published online Oct. 25 in JAMA Cardiology. Tufik R. Assad, M.D., from Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues conducted a retrospective cohort study involving patients undergoing routine RHC for clinical indication. Patients were classified according to mean pulmonary arterial pressure (mPAP) values as reference, borderline PH, and PH (mPAP values of ≤18, 19 to 24, and ≥25 mmHg, respectively). The researchers found that the prevalence of PH and borderline PH was 62 and 18 percent, respectively, among 4,343 patients. Independent associations were seen for advanced age, features of the metabolic syndrome, and chronic heart and lung disease with increased likelihood of borderline PH versus reference patients. Borderline PH was correlated with increased mortality compared with reference patients after adjustment for 34 variables (hazard ratio, 1.31). With higher mPAP there was an incremental increase in the risk of death, without an observed threshold. Sixty-one percent of the 70 patients with borderline PH who underwent repeated RHC had developed overt PH, with a 5 mmHg median increase in mPAP (interquartile range, -1 to 11 mmHg; P < 0.001).

Conjugated linoleic acid (CLA) supplementation is associated with an increase in serum C-reactive protein (CRP) concentration, according to a review and meta-analysis published online May 29 in Cardiovascular Therapeutics. Mohsen Mazidi, Ph.D., from the Chinese Academy of Sciences in Beijing, and colleagues conducted a systematic review and meta-analysis to examine the impact of CLA supplementation on serum CRP. Data were included from 14 studies. The researchers found that following supplementation with CLAs there was a significant increase in serum CRP concentrations (weighted mean difference, 0.63 mg/dL; 95 percent confidence interval, 0.13 to 1.13; heterogeneity P = 0.026); these findings were robust in sensitivity analyses. The changes in serum CRP levels were found to be independent of CLA supplementation dosage (slope, −0.02; 95 percent confidence interval, −0.10 to 0.12; P = 0.889) or follow-up duration (slope, 0.271; 95 percent confidence interval, −0.05 to 0.59; P = 0.098). "This meta-analysis suggests that CLA supplementation is associated with an increase in plasma CRP concentrations and a reduction in serum adiponectin concentrations, which indicates that CLA supplements have a pro-inflammatory effect," the authors write.

35th Critical Care nursing & Nurse Practitioners Conference is organized by Conferenceseries LLC and would be held during Sep 28 - 29, 2017 at Berlin, Germany. The target audience for this medical event basically for Scientists, Doctors, Professors, Nursing Lecturers, Nurses, Pharmaceutical Industries, Healthcare Industries, Directors of Association and Societies.

Higher dietary total fiber and fruit fiber is protective against bone loss at the femoral neck in men, according to a study published online Oct. 12 in the Journal of Bone and Mineral Research. Zhaoli Dai, Ph.D., from the Boston University School of Medicine, and colleagues examined the correlation between dietary fiber, assessed using the Willett food frequency questionnaire, and bone loss at the femoral neck, trochanter, and lumbar spine in older men and women. Bone mineral density was measured using dual-energy X-ray absorptiometry at baseline (1996 to 2011) and in 2001 to 2005 and 2005 to 2008 among 792 men and 1,065 women. The researchers found that in men, but not women, higher dietary total fiber and fruit fiber was protective against bone loss at the femoral neck (P = 0.003 and 0.008, respectively). Compared with men in quartile 1 of fiber intake, those in quartiles 2 to 4 had significantly less bone loss at the femoral neck (all P < 0.04). There were no associations with hip bone loss in women; fiber from vegetables seemed protective against spine bone loss in women but not men. No correlations were seen for cereal fiber or nut and legume fiber with bone loss in men or women.

Dual-graft (DG) adult living donor liver transplantation (ALDLT) with ABO-incompatible (ABOi) and ABO-compatible (ABOc) graft combination is associated with high rates of graft survival, with no significant difference for ABOi and ABOc grafts, according to research published online July 31 in the American Journal of Transplantation. Jae Hyun Kwon, M.D., from the University of Ulsan College of Medicine in Seoul, South Korea, and colleagues conducted a retrospective review of medical records of patients who underwent ABOi DG ALDLT between 2008 and 2014. The authors also assessed the graft regeneration rate using computed tomography volumetric analysis. During a mean follow-up of 57.0 ± 22.4 months, the researchers found that the one-, three-, and five-year patient survival rate was 96.4 percent. The rate of graft survival at one-, three-, and five-years was 96.4, 94.2, and 92.0 percent, respectively; ABOc and ABOi grafts did not differ significantly (P = 0.145). No significant differences were seen between ABOc and ABOi grafts in the biliary complication rate (P = 0.195). There was no significant difference in regeneration rates for ABOi and ABOc grafts. "DG ALDLT with ABOi and ABOc graft combination seems to be a feasible option for expanding the donor pool without additional donor risks," the authors write.

Ropinirole, bromocriptine, and piribedil are associated with the highest incidence rates of adverse effects in Parkinson's disease, according to a review published online Sept. 4 in CNS Neuroscience & Therapeutics. Bao-Dong Li, from the Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine in China, and colleagues conducted a systematic review to compare the adverse effects of 11 drugs used to treat Parkinson's disease. Data were included from 24 randomized controlled trials. The researchers found that, compared with placebo, the incidence of adverse reactions of ropinirole, rotigotine, entacapone, and sumanirole were higher in terms of nausea. The incidence rates of dyskinesia side effects were highest with ropinirole, while in terms of patients' hallucination, pramipexole was significantly higher. The surface under the cumulative ranking curve values of all drugs showed that the incidence of adverse reaction of pergolide was relatively high (nausea, 83.5 percent; hallucination, 79.8 percent); the incidence of dyskinesia and somnolence was higher with ropinirole (80.5 and 69.4 percent); in terms of dizziness, the incidence of adverse reaction of piribedil was higher (67.0 percent), and in terms of constipation, the incidence of bromocriptine was relatively high (62.3 percent). "In addition to current forms of treatment, we hope that our results can produce useful information for further development of new drugs to treat Parkinson's disease based on the natures of each drug," the authors write.

Water - Based Interventions for the Pediatric Therapies is organized by Texas Children's Hospital and will be held during Mar 03 - 04, 2018 at Blue Lagune Therapy - Aquatic & Land Physical Therapy, Katy, Texas, United States of America. This CME Conference has been approved for a maximum of 16 CCUs Credits. Course Description: This Course is designed to rapidly introduce pediatric therapists to motor, sensory and play-based interventions in water. Participants will create a series of aquatic therapeutic movements, tasks, or exercises designed to alleviate the most common problems associated with the pediatric population and then adapte these ideas to novel situations. Participants will briefly examine research which supports aquatic therapy for the child and explore contraindications, including prevailing precaution myths. Course Objectives : * Discriminate between aquatic precautions and contraindications specific to the pediatric client. Defend any choice, on a case-by-case basis, to label a condition as a precaution and not as a contraindication. * Explain why aquatic therapy may be the treatment of choice if (a) the patient has poor head or trunk righting/control, (b) the patient has spasticity, (c) the patient has difficulty with transitional movements; (d) the patient has poor sensory processing; (e) the patient has speech/language deficits; or (f) research supports its use. * Design a sample aquatic treatment session demonstrating 2 ways to divide labor between PT, OT and SLP. Compare and contrast 5 ways that the goals of 3 different disciplines should differ. Recommend 3 ways to co-treat in water and be reimbursed for the services provided. * Originate, integrate, and combine ideas into a plan to implement augmentative communication in the therapy pool setting. Incorporate low-tech augmentative communication methods during labs to improve communication. * Gather and organize the latest aquatic research to bolster the case for treatment and to aid in t

Mayo Clinic Hospital Medicine: Managing Complex Patients is organized by Mayo Clinic and would be held during Nov 08 - 11, 2017 at Loews Ventana Canyon Resort, Tucson, Arizona, United States Of America. The target audience for this medical event for inpatient care providers including physicians, nurse practitioners and physician assistants. Hospitalists are defined as those who spend most of their professional practice caring for hospitalized patients. This CME Conference has been approved with a maximum of 25.25 AMA PRA Category 1 Credits. Hospital Medicine is the fastest growing medical specialty and requires a diverse skill set. Hospital-based health care providers must be able to diagnose and manage a wide variety of clinical conditions, coordinate transitions of care, provide perioperative management to surgical patients and contribute to quality improvement and hospital administration. This program is specifically designed to ensure that participants augment their skill set to meet these many challenges in an effort to enhance the delivery of health care and provide better patient outcomes. Using an interactive, case-based format, key highlights from most major areas of hospital medicine will be presented. Conference Objectives are : * Classify a patient presenting with MI according to the most recent guidelines. * Select the appropriate indications for troponin testing. * Manage a patient with subsegmental pulmonary embolism. * Define sepsis according to the most recent clinical guidelines. * Select the appropriate antibiotics for a hospitalized patient with health-care associated pneumonia. * List strategies to improve the mobility of elderly patients in the hospital. * Manage a patient admitted to the hospital with diabetic ketoacidosis. * Recognize common sources of cognitive bias and heuristics to minimize their impact on patient care. * Order the appropriate tests for a hospitalized patient with a newly-diagnosed pleural effusion. * List novel the

For patients with acute coronary syndromes (ACS), diabetes mellitus (DM), but not pre-DM, is associated with an increased risk of major adverse cardiac events (MACE), according to a study published online Oct. 18 in the Journal of the American College of Cardiology. Serdar Farhan, M.D., from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the impact of pre-DM on coronary plaque characteristics and ischemic outcome in patients with ACS. Participants underwent quantitative coronary angiography, grayscale intravascular ultrasound (IVUS), and radiofrequency IVUS after successful percutaneous coronary intervention. Patients were categorized based on their glucometabolic status as normal glucose metabolism (NGM; 162 patients), pre-DM (202 patients), and DM (183 patients). The researchers found that there were no significant between-group differences with respect to IVUS findings indicative of vulnerable plaques. Compared to patients with pre-DM or NGM, patients with DM had a higher crude rate of MACE (25.9 versus 16.3 and 16.1 percent; P = 0.03 and 0.02, respectively). Using NGM as the reference group, DM, but not pre-DM, was correlated with increased risk of MACE in an adjusted model (hazard ratios, 2.2 [95 percent confidence interval, 1.25 to 3.86; P = 0.006] and 1.29 [95 percent confidence interval, 0.71 to 2.33; P = 0.41]).

Liraglutide treatment for weight management is not associated with increased risk of cardiovascular events, according to a study published online Sept. 26 in Diabetes, Obesity and Metabolism. Melanie J. Davies, M.D., from the University Hospitals of Leicester NHS Trust in the United Kingdom, and colleagues conducted post hoc analysis using data from 5,908 participants in five randomized, double-blind, placebo-controlled clinical trials of liraglutide, a glucagon-like peptide-1 receptor agonist approved for weight management, in order to assess cardiovascular risk. The researchers found that with liraglutide (3.0 mg), eight participants had positively adjudicated cardiovascular events (1.54 events/1,000 person-years), compared to 10 participants in the comparators group (3.65 events/1000 person-years). Compared to the non-liraglutide group, the hazard ratio for 3.0 mg liraglutide treatment was 0.42 (95 percent confidence interval, 0.17 to 1.08).